Etminan M, et al. - Using data from the FDA’s adverse reporting system database, researchers examined the link between fluoroquinolones (FQs) and the risk of aortic and mitral regurgitation in this disproportionality analysis and case-control study. They used a random sample of 9,053,240 patients from the US PharMetrics Plus database (IQVIA). For the disproportionality analysis, the estimated OR was 1.45. In the case-control investigation, 12,505 cases and 125,020 controls were identified. For current users of FQ vs amoxicillin and azithromycin users, the estimated adjusted rate ratios (RRs) were 2.40 and 1.75, respectively. For recent and past FQ users vs amoxicillin users, the adjusted RRs were 1.47 and 1.06, respectively. Current use was associated with the highest risk of aortic and mitral regurgitation, followed by recent use. In relation to past use of FQs, no risk was observed.